Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer

BackgroundHematospermia following prostate radiation therapy is a benign and often self-limiting side effect. However, it may be bothersome to some men and their partners with a negative impact on sexual quality of life (QOL). This study sought to evaluate the incidence, duration, and resolution of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarthak Shah, Tamir Sholklapper, Michael Creswell, Abigail Pepin, Jonathan Cantalino, Ryan Andrew Hankins, Simeng Suy, Sean P. Collins
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	prostate cancer SBRT (stereotactic body radiation therapy) CyberKnife hematospermia 5-alpha reductase inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/33101e7ff83b41a9a620ff23b2f516ef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33101e7ff83b41a9a620ff23b2f516ef
record_format	dspace
spelling	oai:doaj.org-article:33101e7ff83b41a9a620ff23b2f516ef2021-11-30T21:06:07ZBothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer2234-943X10.3389/fonc.2021.765171https://doaj.org/article/33101e7ff83b41a9a620ff23b2f516ef2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.765171/fullhttps://doaj.org/toc/2234-943XBackgroundHematospermia following prostate radiation therapy is a benign and often self-limiting side effect. However, it may be bothersome to some men and their partners with a negative impact on sexual quality of life (QOL). This study sought to evaluate the incidence, duration, and resolution of hematospermia in patients following stereotactic body radiation therapy (SBRT) for prostate cancer.Methods227 patients treated with SBRT from 2013 to 2019 at Georgetown University Hospital for localized prostate carcinoma with a minimum follow up of two years were included in this retrospective review of data that was prospectively collected. Patients who were greater than 70 years old and/or received hormonal therapy were excluded. Hematospermia was defined as bright red blood in the ejaculate. Time points for data collection included initial consultation, pre-treatment, 1-, 3-, 6-, 9-, 12-, 18-, 24-month. All patients were treated with the CyberKnife Radiosurgical System (Accuray). Data on hematospermia including duration, resolution and recurrence was collected. Utilization of 5-alpha reductase inhibitors was documented at each visit.Results227 patients (45 low-, 177 intermediate-, and 5 high-risk according to the D’Amico classification) at a median age of 65 years (range 47-70) received SBRT for their localized prostate cancer. The 2-year cumulative incidence of hematospermia was 5.6%(14 patients). For these patients, all but one patient (93%) saw resolution of their hematospermia by two years post-SBRT. The median time for hematospermia was 9 months post-treatment. Of the 14 patients who reported hematospermia, 70% were managed with 5-alpha reductase inhibitors. Hematospermia was transient in most patients with 70% of the men reporting resolution by the next follow-up visit.ConclusionThe incidence of bothersome hematospermia following SBRT was low. Hematospermia, as noted by other studies, often self-resolves. 5-alpha reductase inhibitors may lead to quicker resolution of bothersome hematospermia.Sarthak ShahTamir SholklapperMichael CreswellAbigail PepinJonathan CantalinoRyan Andrew HankinsSimeng SuySean P. CollinsFrontiers Media S.A.articleprostate cancerSBRT (stereotactic body radiation therapy)CyberKnifehematospermia5-alpha reductase inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	prostate cancer SBRT (stereotactic body radiation therapy) CyberKnife hematospermia 5-alpha reductase inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	prostate cancer SBRT (stereotactic body radiation therapy) CyberKnife hematospermia 5-alpha reductase inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sarthak Shah Tamir Sholklapper Michael Creswell Abigail Pepin Jonathan Cantalino Ryan Andrew Hankins Simeng Suy Sean P. Collins Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
description	BackgroundHematospermia following prostate radiation therapy is a benign and often self-limiting side effect. However, it may be bothersome to some men and their partners with a negative impact on sexual quality of life (QOL). This study sought to evaluate the incidence, duration, and resolution of hematospermia in patients following stereotactic body radiation therapy (SBRT) for prostate cancer.Methods227 patients treated with SBRT from 2013 to 2019 at Georgetown University Hospital for localized prostate carcinoma with a minimum follow up of two years were included in this retrospective review of data that was prospectively collected. Patients who were greater than 70 years old and/or received hormonal therapy were excluded. Hematospermia was defined as bright red blood in the ejaculate. Time points for data collection included initial consultation, pre-treatment, 1-, 3-, 6-, 9-, 12-, 18-, 24-month. All patients were treated with the CyberKnife Radiosurgical System (Accuray). Data on hematospermia including duration, resolution and recurrence was collected. Utilization of 5-alpha reductase inhibitors was documented at each visit.Results227 patients (45 low-, 177 intermediate-, and 5 high-risk according to the D’Amico classification) at a median age of 65 years (range 47-70) received SBRT for their localized prostate cancer. The 2-year cumulative incidence of hematospermia was 5.6%(14 patients). For these patients, all but one patient (93%) saw resolution of their hematospermia by two years post-SBRT. The median time for hematospermia was 9 months post-treatment. Of the 14 patients who reported hematospermia, 70% were managed with 5-alpha reductase inhibitors. Hematospermia was transient in most patients with 70% of the men reporting resolution by the next follow-up visit.ConclusionThe incidence of bothersome hematospermia following SBRT was low. Hematospermia, as noted by other studies, often self-resolves. 5-alpha reductase inhibitors may lead to quicker resolution of bothersome hematospermia.
format	article
author	Sarthak Shah Tamir Sholklapper Michael Creswell Abigail Pepin Jonathan Cantalino Ryan Andrew Hankins Simeng Suy Sean P. Collins
author_facet	Sarthak Shah Tamir Sholklapper Michael Creswell Abigail Pepin Jonathan Cantalino Ryan Andrew Hankins Simeng Suy Sean P. Collins
author_sort	Sarthak Shah
title	Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_short	Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_full	Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_fullStr	Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_full_unstemmed	Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_sort	bothersome hematospermia following stereotactic body radiation therapy for prostate cancer
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/33101e7ff83b41a9a620ff23b2f516ef
work_keys_str_mv	AT sarthakshah bothersomehematospermiafollowingstereotacticbodyradiationtherapyforprostatecancer AT tamirsholklapper bothersomehematospermiafollowingstereotacticbodyradiationtherapyforprostatecancer AT michaelcreswell bothersomehematospermiafollowingstereotacticbodyradiationtherapyforprostatecancer AT abigailpepin bothersomehematospermiafollowingstereotacticbodyradiationtherapyforprostatecancer AT jonathancantalino bothersomehematospermiafollowingstereotacticbodyradiationtherapyforprostatecancer AT ryanandrewhankins bothersomehematospermiafollowingstereotacticbodyradiationtherapyforprostatecancer AT simengsuy bothersomehematospermiafollowingstereotacticbodyradiationtherapyforprostatecancer AT seanpcollins bothersomehematospermiafollowingstereotacticbodyradiationtherapyforprostatecancer
_version_	1718406254142947328

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer

Ejemplares similares